Mucin fusion polypeptide vaccines, compositions and methods...

Details Mucin fusion polypeptide vaccines, compositions and methods... Mucin fusion polypeptide vaccines, compositions and methods...

2003-04-22

2011-10-11

Navarro, Albert (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S001110, C424S001410, C424S001490, C424S001530, C424S001570, C424S130100, C424S133100, C424S134100, C424S178100, C424S183100, C424S184100, C424S185100, C424S196110, C424S197110, C424S278100

Reexamination Certificate

active

08034351

ABSTRACT:
The present invention provides compositions and methods for augmenting vaccine immunogenicity using mucin-immunoglobulin fusion proteins.

REFERENCES:
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5516964 (1996-05-01), Umansky et al.
patent: 5556946 (1996-09-01), Fujisawa et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5879675 (1999-03-01), Galili et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6344203 (2002-02-01), Sandrin et al.
patent: 6361775 (2002-03-01), Galili et al.
patent: 6943239 (2005-09-01), Holgersson et al.
patent: 415731 (1991-03-01), None
patent: WO 87/00329 (1987-01-01), None
patent: WO 90/07936 (1990-07-01), None
patent: WO 94/08598 (1994-04-01), None
patent: WO 95/24924 (1995-09-01), None
patent: WO 98/34957 (1998-06-01), None
patent: WO 98/34957 (1998-08-01), None
patent: WO 98/42750 (1998-10-01), None
Apostolopoulos et al. 1999. J. Mol. Med. Vo. 77: 427-436.
Henion et al. 1997. Vaccine. vol. 15(11): 1174-1182.
Jining et al. 1997. Transplanation. 1997. vol. 63(11):1673-1682 [prinout has pp. 1-14].
Jining et al. 1997. Transplanation. 1997. vol. 63(11)1673-1682 [prinout has pp. 1-14].
Henion et al. 1997. Vaccine. vol. 15(11): 1174-1182.
Baldus et al. 2004. Critical Rev. Clin. Lab. Sci. vol. 41(2): 189-231.
Henke et al (J. of Immunology. 2000. vol. 164:pp. 2131-41).
R& D Systems: Technical Information; Cytokine Bulletin: Viral Cytokines (Jul. 1, 1998).
Henion, et al.,Vaccine, 15(11):1174-1182 (1997).
LaTemple, et al.,Subcell. Biochem., 32:361-379 (1999).
International Search Report for PCT/IB03/02207, mailing date: Dec. 5, 2003.
Baldari et al., “A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1β inSaccharomyces cerevisiae”, EMBO J., 6:229-234 (1987).
Barany et al., “Solid-phase peptide synthesis: a silver anniversary report”,Intl. J. Peptide Protein Res., 30(6):705-739 (1987).
Galili et al., “Preparation of Autologous Leukemia and Lymphoma Vaccines Expressing α-Gal Epitopes”,J. Hematother. Stem Cell Res., 10(4):501-511 (2001).
Galili et al., “Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity”,Immunology Today, 18(6):281-285 (1997).
GenBank Accession No. A57468, Oct. 12, 1999.
GenBank Accession No. AAA73558, Jul. 31, 1995.
GenBank Accession No. AJ417832, Oct. 21, 2008.
GenBank Accession No. AK016248, Sep. 19, 2008.
GenBank Accession No. BAB30163, Sep. 19, 2008.
GenBank Accession No. CAD10625, Oct. 21, 2008.
GenBank Accession No. L36150, Mar. 7, 1995.
GenBank Accession No. NM—009151, Jun. 7, 2009.
GenBank Accession No. NM—145650, Dec. 21, 2008.
GenBank Accession No. NP—033177, Jun. 7, 2009.
GenBank Accession No. NP—663625, Dec. 21, 2008.
GenBank Accession No. P50127, Jun. 16, 2009.
GenBank Accession No. XM—006867, Aug. 1, 2002.
GenBank Accession No. XM—140694, Oct. 8, 2002.
GenBank Accession No. XP—006867, Aug. 1, 2002.
GenBank Accession No. XP—140694, Oct. 8, 2002.
Goldspiel et al., “Clinical Fronteirs: Human gene therapy”,Clin. Pharm., 12:488-505 (1993).
Kaiser et al., “Peptide and protein synthesis by segment synthesis-condensation”,Science, 243:187-198 (1989).
Kappelmayer et al., “Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias”,Br. J. Heamatol., 115(4):903-909 (2001).
Kaufman et al., “Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells”,EMBO J., 6:187-195 (1987).
Kent, “Chemical synthesis of peptides and proteins”,Ann. Rev. Biochem., 57:957-989 (1988).
Koller et al., “Inactivating theβ2-microgloblin locus in mouse embryonic stem cells by homologous recombination”,Proc. Natl .Acad .Sci .U.S.A., 86:8932-8935 (1989).
Kurjan et al., “Structure of a yeast pheromone gene (MF α): a putative α-factor precursor contains four tandem copies of mature alpha-factor”,Cell, 30(3):933-943 (1982).
Loeffler et al., “Gene Transfer into Primary and Established Mammalian Cell lines with Lipopolyamine-Coated DNA”,Meth Enzymol., 217:599-618 (1993).
Lucklow et al., “High Level Expression of Nonfused Foreign Genes withAutographa californicanuclear Polyhedrosis Virus Expression Vectors”,Virology, 170:31-39 (1989).
Reis et al., “Streptococcal Fc receptors. II. Comparison of the reactivity of a receptor from a group C streptococcus with staphylococcal protein A”,J. Immunol., 132:3098-3102 (1984).
Schultz et al., “Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus”,Gene, 54(1):113-123 (1987).
Seed, “An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2”,Nature, 329(6142):840-842 (1987).
Smith et al.,“Production of human beta interferon in insect cells infected with a baculovirus expression vector.”Mol. Cell. Biol., 3:2156-2165 (1983).
Stemple et al., “Isolation of a Stem Cell for Neurons and Glia from the Mammalian Neural Crest”,Cell, 71:973-985 (1992).
Wada et al., “Codon usage tabulated from the GenBank genetic sequence data”,Nucl. Acids Res., 20:2111-2118 (1992).
Wu et al., “Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System”,J. Biol. Chem., 262:4429-4432 (1987).

Affiliated with

Also associated with

Rating

Mucin fusion polypeptide vaccines, compositions and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mucin fusion polypeptide vaccines, compositions and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mucin fusion polypeptide vaccines, compositions and methods... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4287629